Gastric cancer
Conditions
Interventions
Experiment Group:DC vaccine combined with routine treatment
Control Group:conventional therapy
Sponsors
Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged=18 years old; (2) patients with gastric cancer according to the NCCN guideline (2017.V5); (3) surgical resection of the tumor; (4) ECOG score between 0 and 2 or KPS higher than 70; (5) criteria of the laboratory examination results within 1 as follow: 1) the white blood cells (WBC) =3×10^9/L; 2) platelet (PLT)=80 x 10^9/L, hemoglobin (Hb)=80g/L; 3) total bilirubin (TBI) = 1.5x normal level (2mg/dl); 4) alanine aminotransferase (ALT), glutamate transaminase (AST) = 2 x normal level; 5) creatinine (Cr) = 1.5x normal value; 6) coagulation parameters (PT, APTT in normal range); (6) voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: (1) serious uncontrolled medical diseases, viral hepatitis, organ dysfunction and myocardial infarction (during 3 months); (2) the patients combine with heart, kidney and lung diseases were determined: 1) three or higher levels of cardiopulmonary dysfunction and severe renal disease (refer to CTCAE4.0 criteria); 2) previous diagnosis of coronary heart disease, myocardial ischemia, myocardial infarction, arrhythmia (atrial tachycardia, atrial fibrillation, continuous ventricular tachycardia,et al.); (3) patients who are using immunosuppressive drugs or long-term immunosuppressive agents after organ transplantation; (4) the human immunodeficiency virus (HIV) tested positive for active infection within 30 days before treatment, including fever of unknown cause (axillary temperature >37); (5) breast-feeding, pregnant women or planned pregnancy; (6) the patients participate in other clinical trialsenter clinical within 30 days; (7) patients with t-cell lymphoma; (8) patients with severe autoimmune diseases; (9) patients with allergies, especially those with il-2; (10) recent history of active bleeding; (11) mental illness and severe depression.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;progression free survival;Tumor markers;Peripheral blood lymphocyte subsets;Karnofsky Performance Scale Index;Tumor lesions assessment;Vital signs;Blood Routine Test;Urine Routine Test; | — |
Countries
China
Contacts
Public ContactYu-min Li
Lanzhou University
Outcome results
None listed